R&D wins beyond cystic fibrosis, with the povetacicept FDA decision coming for IgA nephropathy. Click for this VRTX update.

In this video, we provide essential "math help" by explaining the process of "completing the square" to convert "quadratic ...

The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals ...

Typically, organizations do not lack information. Organizations are lacking usable information. Company policies reside in various PDF files. Product features can be found in multiple documents. Help ...

👉 Learn how to graph quadratic equations by completing the square. A quadratic equation is an equation of the form y = ax^2 + bx + c, where a, b, and c are constants. The graph of a quadratic ...

Google $GOOGL launched the Gemini Enterprise Agent Platform this week, a product the company describes as the evolution of Vertex AI that will absorb all of Vertex AI ...

Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

Now, here's the reason I would buy and hold Vertex for the long term. It might surprise you when I say it doesn't have to do with the company's work beyond CF. Instead, I would hold onto this company ...